Progyny, Inc. (PGNY) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Progyny, Inc. (PGNY) Healthcare & Pipeline Overview

Progyny, Inc. focuses on fertility and family building benefits solutions for employers in the U.S., offering personalized support and a selective network of specialists. With an integrated pharmacy benefits solution, Progyny Rx, the company addresses medication needs during treatment, positioning itself as a comprehensive solution in the healthcare benefits market.

What Is the Investment Thesis for PGNY?

Progyny, Inc. presents a notable research candidate within the healthcare benefits sector. The company's focus on fertility and family building benefits caters to a growing demand from employers seeking to attract and retain talent. Progyny's differentiated benefits plan design, personalized support services, and integrated pharmacy solution (Progyny Rx) provide a comprehensive offering that sets it apart from competitors. With a market capitalization of $2.02B and a P/E ratio of 32.1, Progyny demonstrates solid financial performance. A profit margin of 5.2% and a gross margin of 24.1% indicate efficient operations. Key growth catalysts include the increasing adoption of fertility benefits by employers and the expansion of Progyny's network of specialists. However, potential risks include competition from other benefits providers and changes in healthcare regulations. The company's beta of 0.99 suggests moderate volatility relative to the market.

Based on FMP financials and quantitative analysis

PGNY Key Highlights

Market Cap of $2.02B reflects investor confidence in Progyny's growth potential within the fertility benefits market.

• P/E Ratio of 32.1 indicates a premium valuation, suggesting expectations of future earnings growth.
• Profit Margin of 5.2% demonstrates the company's ability to generate profit from its revenue.
• Gross Margin of 24.1% showcases the efficiency of Progyny's service delivery and cost management.
• Beta of 0.99 suggests that Progyny's stock price volatility is similar to the overall market.

Who Are PGNY's Competitors?

PGNY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PGNY's Key Strengths?

Specialized expertise in fertility benefits.

• Integrated benefits solution (Progyny Rx).
• Personalized member support services.
• Selective network of fertility specialists.

What Are PGNY's Weaknesses?

Reliance on employer-sponsored benefits.

• Limited geographic presence (primarily US).
• Relatively small market capitalization compared to larger healthcare companies.
• Profit margin could be higher.

What Could Drive PGNY Stock Higher?

Increasing adoption of fertility benefits by employers.

• Expansion of Progyny's network of fertility specialists.
• Potential new partnerships with large corporations.
• Launch of new product offerings to address unmet needs.

What Are the Key Risks for PGNY?

Rich valuation — a P/E of 32.1 runs well above the Healthcare sector’s ~22x, leaving little room for a miss.

• Competition from other benefits providers.
• Changes in healthcare regulations.
• Economic downturn affecting employer spending on benefits.
• Reliance on employer-sponsored benefits.

What Are the Growth Opportunities for PGNY?

• Expanding Employer Partnerships: Progyny has the opportunity to expand its partnerships with employers across various industries. By targeting large corporations and smaller businesses, Progyny can increase its market share and revenue. The market for employer-sponsored fertility benefits is estimated to reach several billion dollars in the coming years, providing a significant growth runway for Progyny. Timeline: Ongoing.
• Geographic Expansion: While currently focused on the United States, Progyny could explore geographic expansion opportunities in other countries with growing demand for fertility services. This could involve partnering with local healthcare providers and adapting its benefits solutions to meet the specific needs of different markets. Timeline: Within the next 3-5 years.
• Enhancing Technology Platform: Progyny can further enhance its technology platform to improve the member experience and streamline operations. This could involve developing new features for its mobile app, such as personalized treatment plans and virtual consultations with fertility specialists. Timeline: Ongoing.
• Strategic Acquisitions: Progyny could pursue strategic acquisitions of complementary businesses in the fertility and family building space. This could include acquiring fertility clinics, pharmacy benefit managers, or technology companies to expand its service offerings and market reach. Timeline: Opportunistic.
• Developing New Product Offerings: Progyny can develop new product offerings to address unmet needs in the fertility and family building market. This could include offering specialized programs for specific patient populations, such as LGBTQ+ individuals or women with recurrent pregnancy loss. Timeline: Within the next 2-3 years.

What Are PGNY's Competitive Advantages?

• Specialized Expertise: Progyny's deep understanding of the fertility benefits market and its ability to provide personalized support services create a competitive advantage.
• Integrated Solution: The company's integrated approach, combining benefits plan design, personalized support, and pharmacy services, differentiates it from competitors.
• Selective Network: Progyny's selective network of fertility specialists ensures high-quality care for its members.
• Data and Technology: Progyny's technology platform and data analytics capabilities enable it to optimize its services and improve member outcomes.

What Does PGNY Do?

Progyny, Inc., initially founded as Auxogyn, Inc. in 2008 and rebranded in 2015, is a benefits management company headquartered in New York City. The company specializes in providing fertility and family building benefits solutions to employers across the United States. Progyny's core offering includes a differentiated benefits plan design, which aims to provide comprehensive coverage for fertility treatments. A key component of their service is personalized concierge-style member support, offering guidance and assistance to individuals navigating fertility treatments. Progyny also maintains a selective network of fertility specialists, ensuring members have access to high-quality care. In addition to its core fertility benefits solution, Progyny offers Progyny Rx, an integrated pharmacy benefits solution. This service provides members with access to medications required during their fertility treatment, streamlining the process and ensuring medication management is integrated with their overall care. Progyny also provides surrogacy and adoption reimbursement programs, further expanding its family building benefits solutions for employers. Progyny serves a diverse range of employers, from large corporations to smaller businesses, seeking to enhance their employee benefits packages and support their employees' family planning needs. With 675 employees, Progyny continues to expand its reach and impact in the fertility benefits market.

What Products and Services Does PGNY Offer?

• Provide fertility benefits solutions for employers.
• Offer personalized concierge-style member support services.
• Maintain a selective network of fertility specialists.
• Provide an integrated pharmacy benefits solution (Progyny Rx).
• Offer surrogacy and adoption reimbursement programs.
• Design differentiated benefits plans for fertility treatments.
• Help employees navigate fertility treatment options.

How Does PGNY Make Money?

• Progyny generates revenue by charging employers a fee for providing fertility and family building benefits to their employees.
• The company negotiates rates with fertility specialists and pharmacies to manage costs and ensure competitive pricing.
• Progyny also generates revenue from its integrated pharmacy benefits solution, Progyny Rx.
• The company focuses on providing high-quality care and personalized support to drive member satisfaction and retention.

What Industry Does PGNY Operate In?

Progyny operates within the healthcare information services industry, specifically focusing on fertility and family building benefits. The market for fertility benefits is growing as more employers recognize the importance of offering these services to attract and retain employees. The competitive landscape includes other benefits providers and specialized fertility clinics. Progyny differentiates itself through its integrated approach, combining benefits plan design, personalized support, and pharmacy services. The increasing awareness of fertility challenges and the rising demand for family building solutions are driving growth in this market segment.

Who Are PGNY's Key Customers?

• Employers of all sizes seeking to enhance their employee benefits packages.
• Employees who are seeking fertility treatments or family building support.
• Large corporations with diverse employee populations.
• Small and medium-sized businesses looking to attract and retain talent.

Company Profile

Progyny, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Pete Anevski. PGNY has traded publicly since 2019.

Progyny, Inc. Financial Trajectory

Progyny, Inc. (PGNY) reported $350.5M in revenue for Q2 FY2026, reflecting 6.7% growth compared to the prior quarter. The company recorded net income of $28.1M, with diluted EPS of $0.34. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, PGNY averaged $0.23 in diluted EPS.

How Progyny, Inc. Is Valued

Progyny, Inc. carries a market capitalization of $2.02B, placing it in the mid-cap category. Analyst price targets span from $30.00 to $40.00, with a consensus of $35.13. At the current price of $25.82, that implies approximately 36% upside potential. Relative to its peer group, PGNY's quantitative score of 91/100 is roughly in line with the peer average of 86/100.

Return on equity for Progyny, Inc. stands at 13.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.7%, showing how much profit it generates from its asset base. PGNY trades at a trailing price-to-earnings ratio of 32.14, above the Healthcare sector average of ~22x. Its free cash flow yield is 8.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.1%, the inverse of the P/E and a quick read on earnings relative to price.

Progyny, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.95 places it in the safe zone, indicating low near-term bankruptcy risk.

Progyny, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4.3% below estimates on average.

Over the past six months, Progyny, Inc. insiders filed 30 SEC Form 4 transactions — 16 sales and 14 purchases. On net that is roughly 167K shares acquired (about $3.3M) — insiders putting money in tends to read as conviction.

PGNY Financials

PGNY Latest News

PGNY Analyst Consensus

PGNY MoonshotScore

PGNY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources